About: http://data.cimple.eu/news-article/865d46520cacac4157008fb725fd414c4116bfae1d84a47b972e2f08

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/865d46520cacac4157008fb725fd414c4116bfae1d84a47b972e2f08 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	AstraZeneca, the British maker of a Covid vaccine with Oxford University, said Thursday its 2020 net profit more than doubled to $3.2 billion thanks to strong sales growth of cancer drugs. Profit after tax, equivalent to 2.64 billion euros, soared 139 percent compared with 2019, the company said in a statement. Revenue from cancer medicines, including Lynparza and Tagrisso, jumped 23 percent. "Despite the significant impact from the pandemic, we delivered double-digit revenue growth" in 2020, chief executive Pascal Soriot said. "The consistent achievements in the pipeline, the accelerating performance of our business and the progress of the Covid-19 vaccine demonstrated what we can achieve," he added. The update comes one day after AstraZeneca said it plans to accelerate production of its Covid vaccine in the second quarter to support EU needs, in a deal with Germany's IDT Biologika. The announcement follows controversy over deliveries of the AstraZeneca-Oxford University jab to the European Union, which had caused tensions between the bloc and the pharmaceutical company. Ahead of the EU's vaccine approval, AstraZeneca sparked fury in Brussels by announcing that it would miss its target of supplying the bloc with 400 million doses, owing to a shortfall at the firm's European plants. While the UK government has vaccinated millions of Britons with the AstraZeneca vaccine since late last year, the company began shipping its jab to the EU only on Friday after the bloc's drug regulator took a comparatively much longer time to recommend its use. bcp/rfj/bmm
schema:headline	Covid vaccine maker AstraZeneca doubles profit
schema:mentions	Types of tennis match Pharmaceutical industry Brussels Pipeline transport Jab University of Oxford AstraZeneca Germany Cancer European Union Pandemic Coronavirus disease United Kingdom Vaccine United States Coronavirus disease 2019 Integrated Device Technology Pascal Soriot
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-02-11 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software